Compare TECX & SLRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | TECX | SLRC |
|---|---|---|
| Founded | 2019 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Finance/Investors Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 618.9M | 691.2M |
| IPO Year | 2018 | 2007 |
| Metric | TECX | SLRC |
|---|---|---|
| Price | $30.57 | $12.74 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 7 |
| Target Price | ★ $75.20 | $15.14 |
| AVG Volume (30 Days) | 209.7K | ★ 347.0K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 10.49% |
| EPS Growth | ★ 40.70 | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $27.11 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.39 | $12.13 |
| 52 Week High | $39.53 | $16.75 |
| Indicator | TECX | SLRC |
|---|---|---|
| Relative Strength Index (RSI) | 39.19 | 49.43 |
| Support Level | $27.30 | $12.47 |
| Resistance Level | $31.39 | $13.33 |
| Average True Range (ATR) | 2.46 | 0.19 |
| MACD | -0.67 | -0.00 |
| Stochastic Oscillator | 3.84 | 47.71 |
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. The company's investment objective is to generate both current income and capital appreciation through debt and equity investments. The company invests principally in leveraged middle-market companies in the form of senior secured loans, financing leases, and to a lesser extent, unsecured loans and equity securities.